抗ＨＬＡ－ＤＱ２．５抗体

Japanese Patent JP7299212

B2

The antibodies of the present invention have specific binding activity to HLA-DQ2.5 and may have binding activity to HLA-DQ2.2 and/or HLA-DQ7.5, but substantially no binding activity to HLA-DQ8, HLA-DQ5.1, HLA-DQ6.3, HLA-DQ7.3, HLA-DR, HLA-DP, or a complex of the invariant chain (CD74) and HLA-DQ2.5. The antibodies bind to HLA-DQ2.5 in the presence of a gluten peptide such as gliadin, i.e., bind to HLA-DQ2.5 forming a complex with the gluten peptide. The antibodies have neutralizing activity against the binding between HLA-DQ2.5 and TCR, and thus block the interaction between HLA-DQ2.5 and an HLA-DQ2.5-restricted CD4+ T cell. The antibodies do not undergo rapid internalization mediated by the invariant chain.

Yusei Okura
Noriyuki Takahashi
Takashi Tsushima
Halfdin Zulkanine
Akihiko Mizorogi

JP2020508640A

June 27, 2023

October 03, 2018

Click for automatic bibliography generation  

Chugai Pharmaceutical Co., Ltd.

C07K16/28

WO2016202805A2

TOLLEFSEN S. et al.,HLA-DQ2 and -DQ8 signatures of gluten T cell epitopes in celiac disease, J. Clin. Invest., 2006, vol. 116, no. 8, p.2226-2236
OZUNA CV. et al., Diversification of the celiac disease α-gliadin complex in wheat: a 33-mer peptide with six overlapping epitopes, evolved following polyploidization, Plant J., 2015, vol. 82, no. 5, p. 794-805

Hatsushi Shimizu
Hideki Kodera
Hirotaka Yamaguchi
Shun Jinbe
Ryuichi Inoue
Toshimitsu Sato
Kousuke Umemura
Koichi Niimi
Tomohiko Kobayashi
Masato Ozeki
Maki Shioda
Kazuya Kawamoto

Previous Patent: Methods of preparing photo-aligned polymeric materials and compositions

Next Patent: Information processing equipment